Aarhus University Seal

About our speakers - AIS12

Tony de Fougerolles

Antonin (Tony) de Fougerolles is a biotech executive with nearly 30 years of R&D experience. He has advanced three major drug modalities to market: mRNA, RNAi, and single-domain antibodies.

As founding CSO of Moderna (2011–2013), he pioneered modified mRNA and LNP delivery technologies. This work underpinned the Moderna and Pfizer/BioNTech COVID-19 vaccines and early DARPA pandemic programs.

At Alnylam (2003–2010), he served as VP Research, developing foundational LNP delivery for RNAi therapeutics. His Alnylam work led to patisiran and the invention of the approved PCSK9 inhibitor inclisiran.

He later served as CSO of Tolerx (2010–2011) focusing on antibody-based immuno-oncology therapies.

As CSO of Ablynx (2013–2017), he advanced caplacizumab to approval and expanded the Nanobody pipeline. Ablynx subsequently reached broad pharma partnerships and was acquired by Sanofi for $4.8 billion.

Most recently, he served as CEO of Evox Therapeutics (2017–2024), scaling exosome-based genetic delivery. At Evox, he built the team from under 6 people and secured $150M in high-profile equity financing.

Across his career, Tony has contributed to multiple Nasdaq IPOs and secured over $80M in research grants.

He has authored over 65 scientific publications and holds 120 issued U.S. patents.

He chairs and serves on seven private and public corporate boards across the US, UK, Europe, and Australia.

Tony holds a Ph.D. in Immunology from Harvard University and completed postdoctoral training at Cambridge.

Ludvig Sollid

Ludvig Sollid is Professor at the University of Oslo and Senior Consultant at Oslo University Hospital - Rikshospitalet. He is also Director of the K.G. Jebsen Coeliac Disease Research Centre. His research focuses on the genetics and immunology of autoimmune diseases, with particular emphasis on coeliac disease. His group has made seminal contributions to understanding the molecular and immunological basis of coeliac disease, including defining the role of HLA genes, identifying HLA-DQ-restricted gluten-reactive T cells in intestinal lesions, characterizing immunogenic gluten peptide sequences, and establishing the role of transglutaminase 2 in disease pathogenesis. His current research focuses on the antigen receptors of T and B cells that recognize the key coeliac disease-associated antigens gluten and transglutaminase 2.

Anna Mathia Klawonn

Anna Mathia Klawonn is Associate Professor at Aarhus University and Group Leader at the Danish Research Institute of Translational Neuroscience (DANDRITE). Her research lies at the interface of neuroscience and immunology and focuses on understanding how immune-to-brain signaling and neural circuits regulate affective states in health and disease. Her group investigates how inflammatory signals and brain-resident immune and glial cells, including microglia and astrocytes, influence neuronal circuits and behavior, with particular emphasis on depression and Parkinson’s disease. Using approaches including chemogenetics, optogenetics, viral tracing, imaging, and behavioral studies, her research aims to define the cellular and molecular mechanisms linking inflammation and neuroimmune signaling to changes in mood and motivation.

Rafick-Pierre Sékaly

Prof. Rafick-Pierre Sékaly, PhD, is a professor and serves as vice-chair of translational medicine in the Department of Pathology and Laboratory Medicine at Emory University School of Medicine in Atlanta, Georgia. For over two decades, Dr. Sékaly's group has been focused on developing a better understanding of the human immune response to vaccines and to chronic viral infections with a specific focus on HIV infection. They have implemented the use of system biology approaches to monitor the diversity of memory T cell and to identify the mechanisms underlying the diversity of memory T cell subsets. They have pioneered the application of systems biology approaches to the understanding of mechanisms of action of the licensed vaccines and adjuvants. They have also shown for the first time the diversity of the mechanism that lead to the establishment and persistence of HIV in different memory T cell subsets. Dr Sékaly obtained his PhD in Biochemistry from the Université de Lausanne in Switzerland where he also completed a postdoctoral fellowship on immunogenetics and molecular biology.

Laurent Mascarell

Laurent Mascarell, PhD, MBA, is Senior Director, Research and Early Development at Stallergenes Greer (Antony, France), where he spearheads innovation initiatives, scientific strategy, and research collaborations across Europe and the US in respiratory and food allergies.

Trained as an immunologist, he holds a PhD in cellular and molecular biology from the University of Paris. Laurent began his career at the Pasteur Institute, studying the mode of action of immunosuppressive drugs used in organ transplantation, and later contributed to the development of a prototype HIV-Tat vaccine with Aventis-Pasteur.

His research interests include biomarkers, allergen characterization, the impact of climate change on allergies, and novel platforms for preclinical and clinical testing in allergic rhinitis, asthma, and food allergy. His work in allergic asthma places particular emphasis on innovative approaches, including bi-therapy combining monoclonal antibodies with allergen immunotherapy.

John Isaacs

John Isaacs, PhD, MBBS, is Professor of Clinical Rheumatology and Director of Therapeutics at Newcastle University, and a Consultant Rheumatologist at Freeman Hospital, Newcastle upon Tyne. John trained in medicine at the University of London and completed a PhD in immunology at Cambridge University, with postgraduate posts in London, Boston and Cambridge before moving into rheumatology. In 1992 he was the first to demonstrate the immunogenicity of a humanised therapeutic antibody, CAMPATH-1H, and has since led pioneering experimental medicine studies that have shaped the design of later generations of biological therapies for rheumatoid arthritis. He now directs Newcastle University's Institute of Cellular Medicine, where he leads a research group focused on therapeutic tolerance induction and the immunopathogenesis of rheumatoid arthritis.

Ignacio Moraga

Ignacio Moraga, PhD, is Co-founder and Chief Scientific Officer of TECregen AG, a Basel-based biotech developing thymopoietic therapies to rejuvenate the thymus and restore immune function. Ignacio trained at Institut Pasteur and at Stanford University, where his work helped define the structural principles behind engineering cytokine-receptor signaling. He then became a Reader/Associate Professor at the University of Dundee, where he led a research group studying how cytokine receptor complexes fine-tune JAK/STAT signaling to control immune cell fate and function. He now applies this expertise at TECregen to engineer novel thymopoietic biologics for immune regeneration.

Michael Ensing

Michael Ensing joined Nykode Therapeutics as CEO in 2017. He is a broadly anchored pharmaceutical professional with extensive experience, from early-stage drug discovery to late-stage development and product launches in biotech and pharma and across all major geographical areas. His career history includes specialist and managerial roles at Takeda and Nycomed. Michael holds a civil engineering (MSc) degree in chemistry specializing in biotechnology from the Technical University of Denmark, and a Graduate Diploma in Business Administration (HD) in organization and leadership from the Copenhagen Business School (CBS).

Jack Elands

Dr. Jack Elands is a serial biotech entrepreneur and executive with extensive experience in drug discovery, development and commercialization. He is Founder and CEO of Adcytherix, a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates for cancer. Previously, he co-founded and led Emergence Therapeutics and Amakem Therapeutics, and served as CEO of BliNK Biomedical and Vitec. Dr. Elands began his career at Marion Merrell Dow and holds a doctorate in neuropharmacology from Utrecht University.